Drug Development SolutionsThe pharmaceutical industry faces an R&D productivity crisis: the cost of bringing an NCE to market (including the cost of failures) was estimated to be around $320 million in 1991, but had risen to over $1.2 billion by 2007. Our goal at CXR is to support informed decision making at all stages of preclinical drug development, thereby driving lead selection and clinical design decisions that give the highest likelihood of approval with the optimal label. We focus on generating early, cost effective and relevant in vitro and (in particular) in vivo data. This data is benchmarked against agreed, rational criteria in order to make selection decisions. 
We provide services and expertise on a fee-for-service basis, and our proprietary models are available to licence.
 Download the Hits-To-Leads brochure here
In vivo screening PK studies.
Small, cost effective PK studies, where multisampling techniques in mouse or rat mean compound and animal use is minimised.
The HRN™ mouse.
A unique mouse model with no hepatic CYP450 activity, that can be used to determine ADME, PK and efficacy in the absence of confounding first-pass metabolism.
transADMET™ mice
Key murine genes involved in the metabolic response to drugs (e.g. PXR, CAR, cytochrome P450s, drug transporters) are replaced with their human equivalents to give a more predictive and “human-like” response.
|
